GlassScriptPhysician profile
Jack D Bissett
NPI 1407874027
$3,354.64
in general payments reported to CMS, 2019-2025
24 companies · $917 in 2025
The $917 reported for 2025 was more than what 77% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $52.55 · 2021: $213 · 2022: $503 · 2023: $559 · 2024: $477 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,952.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $880.34 | 2019-2025 | Yeztugo, Biktarvy, Veklury |
| Viiv Healthcare Company | $531.97 | 2019-2025 | Dovato, Rukobia, Cabenuva |
| Octapharma USA, INC. | $412.94 | 2022-2025 | Octagam Immune Globulin (Human), Panzyga, Cutaquig |
| Astellas Pharma US INC | $316.78 | 2019-2025 | Cresemba |
| Merck Sharp & Dohme LLC | $278.21 | 2019-2025 | Zerbaxa, Prevymis, Dificid |
| Abbvie INC. | $197.01 | 2021-2025 | Avycaz, Dalvance |
| Janssen Products, LP | $99.95 | 2019 | |
| Paratek Pharmaceuticals, INC. | $76.03 | 2024-2025 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $75.85 | 2022-2023 | Livtencity |
| Melinta Therapeutics, LLC | $62.28 | 2019 | |
| Insmed, INC. | $60.23 | 2024-2025 | Arikayce |
| Hospira, INC. | $59.00 | 2024-2025 | |
| Emd Serono, INC. | $50.18 | 2023 | Serostim |
| Cumberland Pharmaceuticals, INC. | $45.16 | 2024-2025 | Vibativ |
| Janssen Biotech, INC. | $37.28 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $33.49 | 2024-2025 | Fetroja |
| Aimmune Therapeutics, INC. | $23.21 | 2024 | |
| Allergan, INC. | $20.58 | 2019 | |
| Smith+Nephew, INC. | $17.03 | 2021 | |
| Pfizer INC. | $16.57 | 2025 | |
| Ferring Pharmaceuticals INC. | $15.82 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $15.70 | 2020 | |
| Theratechnologies INC. | $15.67 | 2019 | |
| Dynavax Technologies Corporation | $13.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Bissett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.